Wall Street brokerages predict that BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) will post ($4.38) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for BeiGene’s earnings, with the lowest EPS estimate coming in at ($4.45) and the highest estimate coming in at ($4.30). BeiGene reported […]
Shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) have been given an average recommendation of “Buy” by the eight ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The […]
Equities research analysts expect BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) to report sales of $332.26 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for BeiGene’s earnings, with the highest sales estimate coming in at $347.62 million and the lowest estimate coming in at $316.90 million. BeiGene reported […]
BeiGene (NASDAQ:BGNE – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is […]
BeiGene (NASDAQ:BGNE – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The brokerage currently has a $179.00 price objective on the stock. Zacks Investment Research‘s price objective points to a potential upside of 7.49% […]